Becton, Dickinson and Company (NYSE:BDX) Releases Earnings Results

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings data on Wednesday. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43, Zacks reports. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company updated its FY 2025 guidance to 14.300-14.600 EPS.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded up $0.85 during mid-day trading on Friday, reaching $228.06. 759,064 shares of the stock traded hands, compared to its average volume of 2,137,293. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The business has a 50-day moving average of $231.90 and a 200 day moving average of $234.05. The stock has a market capitalization of $66.14 billion, a PE ratio of 38.41, a PEG ratio of 1.80 and a beta of 0.40. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.82%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Piper Sandler raised their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company announced that its board has initiated a stock buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.